-
Mashup Score: 1Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD - 14 hour(s) ago
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men’s health.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the future of NMIBC, as well as addressing the practical challenges of bringing these innovations into practice.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Discover the newly approved therapies for NMIBC in the latest peer exchange, featuring expert insights and real-world evidence. Watch now: https://t.co/oTI0CyvR3S #NMIBC https://t.co/Kh46rqnR47
-
-
Mashup Score: 0
Already Registered? Login here. REGISTER NOW Already registered?
Source: studio.mjhassoc.comCategories: General Medicine News, UrologyTweet-
Explore the impact of GEMTESA® (vibegron) in our upcoming live national broadcast! Hear expert insights, review phase 3 COURAGE trial data, and get a patient’s perspective. Register now: https://t.co/0txDcQnzbo Please see full Prescribing Information. https://t.co/3zTJL4dyvk https://t.co/mxgRSsjQG2
-
-
Mashup Score: 3
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
"UCLA has long been a pioneer in SBRT for treating patients who have not yet had surgery, and now with the SCIMITAR trial, we have the first phase 2 data in the world to support this treatment in men who have had surgery," says @AmarUKishan. | @UclaUrology https://t.co/PaCRrR2B8M
-
-
Mashup Score: 1
An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Benjamin Brucker, MD, (@PelvicMedicine) shares specific actions that physicians and other staff can take to ease patient’s anxiety and ensure comfort when administering onabotulinumtoxinA for OAB. @NYUUrology https://t.co/eV9KRAeRKi
-
-
Mashup Score: 9
Nearly 60% of patients taking vibegron remained on treatment at 1 year.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Roger Dmochowski, MD, shares findings on real-world persistence with vibegron for OAB. #AUA25 @VUMCurology https://t.co/XeWV1xtWxo
-
-
Mashup Score: 1
“The use of telemedicine is heavily dependent on supportive legislature,” write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
In a recent article, Tracey Krupski, MD, (@tkrupskiuro) and Jeunice Owens-Walton, MD, (@JeuniceMED) discuss the evolution of telemedicine in urologic oncology and reflect on the legislative landscape surrounding its role in medical care. @uvaurology https://t.co/4w7jPV29yD
-
-
Mashup Score: 3
YĹŤni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The YĹŤni. Fit bladder support significantly reduced pad weights and SUI events compared with a sham device, according to findings from a recently published study. #urology @JEFFObGyn https://t.co/SnsC0UOROd
-
-
Mashup Score: 1Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer - 4 day(s) ago
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The 50% enrollment goal has been met in the phase 2a PROHEAR study, evaluating the safety and efficacy of ACOU085 in preventing cisplatin-induced hearing loss in patients with testicular cancer. #urology https://t.co/g23s448fqr
-
-
Mashup Score: 6
The freedom from re-intervention rate was 71%.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The Optilume drug-coated balloon was associated with durable efficacy and a manageable safety profile in patients with urethral stricture disease, according to 3-year data from ROBUST III. #urology https://t.co/G09lYpT56Z
-
🎧 New on #PearlsAndPerspectives: @AmyPearlman1 talks with men’s health expert @AlexTatem about testosterone therapy—what works, what doesn’t, and why it’s often misunderstood. From injectables to orals to estradiol, this episode has it all. 🔗 Listen: https://t.co/g5ZwKRW9sX https://t.co/0I3dX6dFkQ